Efficacy and Safety of Everolimus with Early Reduction or Elimination of Tacrolimus in 719 de Novo Liver Transplant Recipients - Results at 12 Months

被引：0

作者：

De Simone, P. ^{[1
]}

Nevens, F. ^{[2
]}

Duvoux, C. ^{[3
]}

Koneru, B. ^{[4
]}

McCormack, L. ^{[5
]}

McCaughan, G. ^{[6
]}

Navasa, M. ^{[7
]}

Dong, G. ^{[8
]}

Hexham, J. M. ^{[8
]}

Junge, G. ^{[9
]}

Fung, J. ^{[10
]}

机构：

[1] Univ Pisa, A Osped Univ Pisana, Pisa, Italy

[2] Univ Hosp Gasthuisberg, Leuven, Belgium

[3] Hop Henri Mondor, Creteil, France

[4] Univ Med & Dent New Jersey, Newark, NJ 07103 USA

[5] Hosp Aleman, Buenos Aires, DF, Argentina

[6] Royal Prince Alfred Hosp, Camperdown, NSW, Australia

[7] Hosp Clin I Prov Barcelona, Barcelona, Spain

[8] Novartis Pharmaceut, E Hanover, NJ USA

[9] Novartos Pharma AG, Basel, Switzerland

[10] Cleveland Clin Fdn, Cleveland, OH 44195 USA

来源：

关键词：

D O I：

10.1097/00007890-201211271-01469

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

1556

引用

页码：750 / 750

页数：1